iTeos Therapeutics, Inc. (ITOS)


-0.49 (-4.65%)
Symbol ITOS
Price $10.05
Beta 1.201
Volume Avg. 0.37M
Market Cap 359.608M
Shares () -
52 Week Range 9.81-23.0
1y Target Est -
DCF Unlevered ITOS DCF ->
DCF Levered ITOS LDCF ->
ROE -4.42% Neutral
ROA -4.04% Neutral
Operating Margin -
Debt / Equity 0.87% Neutral
P/E -12.72 Strong Sell
P/B 0.58 Buy


Consensus EPS

Upgrades & Downgrades

Latest ITOS news

Dr. Michel Detheux Ph.D.
NASDAQ Global Market

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.